Fruzaqla® is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC).

Discover the health-related quality of life findings from FRESCO-2, highlighting how Fruzaqla® supports stability and delays deterioration, as analyzed through patient-centered tools.

Learn more about FRESCO-2, the global, randomised, double-blind, multi-centric phase III pivotal Fruzaqla®-study.

Explore the FRESCO-2 lay summary, co-written with patients to simplify key findings and present groundbreaking research in an accessible way.

DDW 2025 in San Diego - and you'll be there every day: with our Daily Reels!

Simple, convenient dosing with once-daily oral Fruzaqla®.¹

In FRESCO-2, the majority of adverse events (AEs) with Fruzaqla® were manageable and predictable^1-3

FRESCO-2 is a global, randomized, double-blind, multicenter phase 3 study, evaluating the efficacy and safety of Fruzaqla® + best supportive care (BSC) vs. Placebo + BSC.^1,2